| Name | 3-Pyridinecarboxamide |
|---|---|
| Synonyms |
Niacinamide
MFCD00006395 Nicotinic acid amide Vitamin- B3 Witamina PP 3-Pyridinecarboxamide Nicotinamide Pyridine-3-carboxamide T6NJ CVZ Dipigyl EINECS 202-713-4 Vi-noctyl |
| Description | Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1. |
|---|---|
| Related Catalog | |
| Target |
PARP-1 Human Endogenous Metabolite |
| In Vitro | Pretreatment with the poly (ADP-ribose) polymerase (PARP) inhibitor nicotinamide is able to prevent HCN2 cell death. When nicotinamide is added prior to t-BuOOH, it is able to prevent neuronal cell death and inhibit apoptosis. Nicotinamide-pretreated neurons have higher expression levels of inhibitors of apoptosis (IAP) genes[1]. Nicotinamide inhibits vasoconstriction by ET. Nicotinamide also alleviates oxidative stress, which exacerbates PE and FGR[3]. |
| In Vivo | Normal and streptozotocin-nicotinamide induced adult male diabetic rats receive quercetin (10, 25 and 50 mg/kg/bw) orally, and cause significant decrease in FBG and cardiac injury marker levels with increased in insulin levels[2]. Nicotinamide improves maternal hypertension, proteinuria, and glomerular endotheliosis in RUPP mice. Moreover, nicotinamide prolongs pregnancies, and improves survival and growth of the embryos in RUPP PE mice[3]. |
| Animal Admin | DM is induced via a single intraperitoneal (i.p) injection of nicotinamide (110 mg/kg/body weight) dissolved in normal saline 15 min prior to streptozotocin (STZ) (55 mg/kg/body weight) injection, which is dissolved in a freshly prepared 0.1mol/Lcitrate buffer (pH 4.5). These injections are given following an overnight fast. Control rats (n=6) are injected with the same amount of solvent. In order to prevent hypoglycemia in the first 24 h following STZ injection, rats are allowed to have free access to water with 5% dextrose (D5W). Three days after STZ-nicotinamide injection, rats with FBG levels greater than 7.0 mM are considered as diabetic. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 257.7±32.0 °C at 760 mmHg |
| Melting Point | 128-131 °C(lit.) |
| Molecular Formula | C6H6N2O |
| Molecular Weight | 122.125 |
| Flash Point | 109.7±25.1 °C |
| Exact Mass | 122.048012 |
| PSA | 55.98000 |
| LogP | -0.24 |
| Appearance | powder | white |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.590 |
| Storage condition | 0-6°C |
| Stability | Stable. Incompatible with strong oxidizing agents. |
| Water Solubility | 1000 g/L (20 ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26;S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 1 |
| RTECS | QS3675000 |
| HS Code | 2933399090 |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |